Limbix Spark Clinical Trial Strategy

2019

2020

2021

2022

2023

Phase I Feasibility Clinical Trial Start

Phase I Feasibility Clinical Trial Completed

Phase II RCT Start

Phase II RCT Completion

FDA Pivotal Trial Start

FDA Pivotal RCT Completion

Phase I Results

Significant reduction in adolescent depressive symptoms

PHQ-8 score
moderately severe
moderate
mild
20.00
17.50
15.00
12.50
10.00
7.50
5.00
Pre-Tx
Week 2
Week 3
Week 4
Week 5
Post-Tx
1 Month
Follow Up

Collaborate with Limbix

Interested in partnering for clinical research? Please contact: research@limbix.com